Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma.

ABSTRACT:

Purpose

Cancer Immunotherapy Trials Network 12 demonstrated safety of pembrolizumab in treating advanced cancer in people with HIV. Here, we report results of the Kaposi sarcoma (KS) cohort.

Methods

In this multicenter phase I trial, we enrolled participants with HIV-associated KS on antiretroviral therapy with CD4⁺ ≥50 cells/μL and HIV plasma RNA <200 copies/mL. Pembrolizumab 200 mg intravenously was administered once every 3 weeks for up to 35 cycles. The primary end point was safety, and the secondary end point was KS response by modified AIDS Clinical Trials Group Criteria.

Results

Thirty-two cisgender men enrolled with baseline median CD4⁺ T-cell count of 274 cells/µL. All but nine participants had received previous systemic KS therapy. Part

SUBMITTER: Lurain K 

PROVIDER: S-EPMC11779594 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature